C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 3, 2017, Pages 513-525

  Shirai, T ^a   Inoue, O ^b   Tamura, S ^c   Tsukiji, N ^a   Sasaki, T ^a   Endo, H ^d   Satoh, K ^b   Osada, M ^b,e   Sato Uchida, H ^a   Fujii, H ^a   Ozaki, Y ^a   Suzuki Inoue, K ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF SHIGA PREFECTURE   (Japan)

^e GUNMA PAZ UNIVERSITY   (Japan)

Author keywords

cancer; inflammation; lectins, C type; platelet; thrombosis

Indexed keywords

C TYPE LECTIN LIKE RECEPTOR 2; HEMOGLOBIN; LECTIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A2B10; OXYGEN; UNCLASSIFIED DRUG; CLEC-2 PROTEIN, MOUSE; GREEN FLUORESCENT PROTEIN; LECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B16F10 CELL LINE; BLOOD CLOTTING; CACHEXIA; CANCER GROWTH; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MELANOMA; MELANOMA CELL LINE; METASTASIS; MOUSE; NONHUMAN; NUTRIENT SUPPLY; OVERALL SURVIVAL; PROGNOSIS; PROTHROMBOTIC STATE; THROMBOCYTE; THROMBOSIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; CHEMISTRY; DISEASE EXACERBATION; EXPERIMENTAL MELANOMA; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; PATHOLOGY; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CELL PROLIFERATION; DISEASE PROGRESSION; GREEN FLUORESCENT PROTEINS; HEMOGLOBINS; LECTINS, C-TYPE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; PLATELET ACTIVATION; PLATELET AGGREGATION; PROGNOSIS; RATS; THROMBOSIS;

EID: 85013080559     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13604     Document Type: Article

References (43)

1. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3: 425–30.
2. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819–26.
3. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295–300.
4. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747–60.
5. Pulcinelli FM, Manzari G, Bartoli M, Faggioni A, Mancusa RL, Pavan A, Sansolini T, Torrisi MR, Gazzaniga PP. Mechanisms of the platelet proaggregating activity of human carcinoma a431 cells. Platelets 1995; 6: 213–20.
6. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74: 282–90.
7. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008; 28: 2997–3006.
8. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost 2011; 9(Suppl 1): 44–55.
9. Kan S, Konishi E, Arita T, Ikemoto C, Takenaka H, Yanagisawa A, Katoh N, Asai J. Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma. J Cutan Pathol 2014; 41: 561–7.
10. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483–8.
11. Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107: 542–9.
12. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007; 282: 25993–6001.
13. Mourao-Sa D, Robinson MJ, Zelenay S, Sancho D, Chakravarty P, Larsen R, Plantinga M, Van Rooijen N, Soares MP, Lambrecht B, Reis e Sousa C. CLEC-2 signaling via Syk in myeloid cells can regulate inflammatory responses. Eur J Immunol 2011; 41: 3040–53.
14. May F, Hagedorn I, Pleines I, Bender M, Vogtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464–72.
15. Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, Vogtle T, Remer K, Braun A, Bosl M, Watson SP, Nieswandt B. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013; 33: 926–34.
16. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010; 285: 24494–507.
17. Hughes CE, Navarro-Nunez L, Finney BA, Mourao-Sa D, Pollitt AY, Watson SP. CLEC-2 is not required for platelet aggregation at arteriolar shear. J Thromb Haemost 2010; 8: 2328–32.
18. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003; 22: 3546–56.
19. Astarita JL, Cremasco V, Fu J, Darnell MC, Peck JR, Nieves-Bonilla JM, Song K, Kondo Y, Woodruff MC, Gogineni A, Onder L, Ludewig B, Weimer RM, Carroll MC, Mooney DJ, Xia L, Turley SJ. The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol 2015; 16: 75–84.
20. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54–61.
21. Inoue O, Hokamura K, Shirai T, Osada M, Tsukiji N, Hatakeyama K, Umemura K, Asada Y, Suzuki-Inoue K, Ozaki Y. Vascular smooth muscle cells stimulate platelets and facilitate thrombus formation through platelet CLEC-2: implications in atherothrombosis. PLoS ONE 2015; 10: e0139357.
22. Tamura S, Suzuki-Inoue K, Tsukiji N, Shirai T, Sasaki T, Osada M, Satoh K, Ozaki Y. Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2. Blood 2016; 127: 1701–10.
23. Osada M, Inoue O, Ding G, Shirai T, Ichise H, Hirayama K, Takano K, Yatomi Y, Hirashima M, Fujii H, Suzuki-Inoue K, Ozaki Y. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem 2012; 287: 22241–52.
24. Lorenz V, Stegner D, Stritt S, Vogtle T, Kiefer F, Witke W, Schymeinsky J, Watson SP, Walzog B, Nieswandt B. Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization. Blood 2015; 125: 4069–77.
25. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff M, Kim YA, Swat W. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 2012; 37: 276–89.
26. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Semin Oncol 2014; 41: 359–69.
27. Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011; 1815: 189–96.
28. Samoszuk MK, Su MY, Najafi A, Nalcioglu O. Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. Am J Pathol 2001; 159: 245–51.
29. de la Fuente C, Pumarola M, Blasco E, Fernandez F, Viu J, Anor S. Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas. Vet J 2014; 200: 387–92.
30. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–4.
31. Frere C, Debourdeau P, Hij A, Cajfinger F, Nonan MN, Panicot-Dubois L, Dubois C, Farge D. Therapy for cancer-related thromboembolism. Semin Oncol 2014; 41: 319–38.
32. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99–111.
33. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–95.
34. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55–63.
35. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713–25.
36. Tormoen GW, Haley KM, Levine RL, McCarty OJ. Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol 2012; 2: 115.
37. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979; 97: 587–600.
38. Zhao Y, Zhang D, Wang S, Tao L, Wang A, Chen W, Zhu Z, Zheng S, Gao X, Lu Y. Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-kappaB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS ONE 2013; 8: e56557.
39. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725–34.
40. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397–408.
41. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904–10.
42. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591–601.
43. Chen M, Ye X, Ming X, Chen Y, Wang Y, Su X, Su W, Kong Y. A novel direct factor Xa inhibitory peptide with anti-platelet aggregation activity from agkistrodon acutus venom hydrolysates. Sci Rep 2015; 5: 10846.